Bing Zhu1, Shavari Dalal, David W Kamp, Xiaoqi Lin. 1. Dept of Pathology, Northwestern Memorial Hospital, Feinberg School of Medicine, Northwestern University, 251 E. Huron St, Galter Pavilion 7-132F, Chicago, IL 60611; xlin@northwestern.edu.
Abstract
OBJECTIVES: To distinguish primary lung adenocarcinoma (PLA) from metastatic adenocarcinoma/malignancy to optimize therapy. METHODS: We investigated the utility of thyroid transcription factor 1 (TTF-1) and napsin A in distinguishing PLA from metastatic adenocarcinoma/malignancy and assessed the frequency of PLA in patients with extrapulmonary malignancy/adenocarcinoma (PLA-EPM/EPA). RESULTS: TTF-1 and napsin A identified PLA in PLA-EPM/ EPA with a sensitivity of 89.4% and 93.3% and a specificity of 93.9% and 94.7%, respectively. PLA was confirmedin 47.4% of PLA-EPM and 40.2% of PLA-EPA. Overall, 38.5% of patients with PLA had EPM. The common organs for PLA-EPA were breast (35.8%), colon (13.2%), and others, whereas the common organs resulting in pulmonary metastasis were the colon (32.8%), breast (28.1%), and others. A patient with a smoking history and without EPM had a higher chance of having PLA. Multiple nodules are not a reliable indication of metastatic adenocarcinoma. CONCLUSIONS: Our results firmly support the role of TTF-1 and napsin A in identifying PLA-EPM/EPA. We reason that all new lung nodules in patients with a history of EPM should be screened using these techniques due to the high frequency of PLA-EPM, which will affect treatment and prognosis of patients with EPM/EPA.
OBJECTIVES: To distinguish primary lung adenocarcinoma (PLA) from metastatic adenocarcinoma/malignancy to optimize therapy. METHODS: We investigated the utility of thyroid transcription factor 1 (TTF-1) and napsin A in distinguishing PLA from metastatic adenocarcinoma/malignancy and assessed the frequency of PLA in patients with extrapulmonary malignancy/adenocarcinoma (PLA-EPM/EPA). RESULTS:TTF-1 and napsin A identified PLA in PLA-EPM/ EPA with a sensitivity of 89.4% and 93.3% and a specificity of 93.9% and 94.7%, respectively. PLA was confirmedin 47.4% of PLA-EPM and 40.2% of PLA-EPA. Overall, 38.5% of patients with PLA had EPM. The common organs for PLA-EPA were breast (35.8%), colon (13.2%), and others, whereas the common organs resulting in pulmonary metastasis were the colon (32.8%), breast (28.1%), and others. A patient with a smoking history and without EPM had a higher chance of having PLA. Multiple nodules are not a reliable indication of metastatic adenocarcinoma. CONCLUSIONS: Our results firmly support the role of TTF-1 and napsin A in identifying PLA-EPM/EPA. We reason that all new lung nodules in patients with a history of EPM should be screened using these techniques due to the high frequency of PLA-EPM, which will affect treatment and prognosis of patients with EPM/EPA.
Authors: Tarek M Aziz; Rasheed A Saad; Jonathan Glasser; Ali N Jilaihawi; Dhruva Prakash Journal: Eur J Cardiothorac Surg Date: 2002-03 Impact factor: 4.191
Authors: Andres Matoso; Kamaljeet Singh; Rafik Jacob; Wesley O Greaves; Rosemarie Tavares; Lelia Noble; Murray B Resnick; Ronald A Delellis; Li J Wang Journal: Appl Immunohistochem Mol Morphol Date: 2010-03
Authors: Koushan Siami; W Glenn McCluggage; Nelson G Ordonez; Elizabeth D Euscher; Anais Malpica; Nour Sneige; Elvio G Silva; Michael T Deavers Journal: Am J Surg Pathol Date: 2007-11 Impact factor: 6.394